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Vitronectin is a glycoprotein involved in many cellular processes including blood 
coagulation, fibrinolysis, and cell/matrix binding.  It interacts with a number of 
macromolecules including heparin, PAI-1, and the thrombin-antithrombin complex.  We 
have studied the interaction of full-length vitronectin and the thrombin-antithrombin 
complex using a Far Western method.  To localize the recognition site for thrombin-
antithrombin binding to vitronectin, sequences for eight overlapping recombinant 
polypeptide sequences of vitronectin (spanning all 459 amino acids) were cloned into the 
pET system.  Expression in BL21(DE3)pLysS Escherichia coli has been achieved for 
seven of the eight 100 amino acid fragments.  Seven polypeptides (amino acids 1-100, 
51-150, 101-200, 151-250, 201-300, 251-350, and 351-459) have been isolated and 
purified using metal-chelating affinity chromatography.  These fragments have been 
tested for interaction with the thrombin-antithrombin pair using the Far Western 
technique.  Results indicate interaction of the complex with vitronectin between amino 
acids 201-300 and possibly at another site near the C-terminal.  Additionally, these 
expressed fragments have served as helpful reagents in mapping the epitopes of three 
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I.  Introduction 
Vitronectin is an adhesive glycoprotein found in both circulation and the 
extracellular matrix (ECM).  It is involved in a number of physiological processes 
including blood coagulation, fibrinolysis, cellular migration, the humoral immune 
response, tumor metastasis, and angiogenesis (1,2).  Its importance as a regulatory 
protein, particularly in maintaining the fine balance between thrombus formation and 
dissolution, cannot be over-emphasized.  Disruption of this balance can result in 
excessive bleeding, disseminated intravascular coagulation, stroke, or myocardial 
infarction .    
Vitronectin plays its diverse and important role in vivo by binding a vast array of 
biological ligands.  These include heparin (3-5), plasminogen activator inhibitor-1 (PAI-
1) (6-10), proteases such as the urokinase-type plasminogen activator (uPA) (11), 
constituents of the extracellular matrix such as collagen (12), the terminal complement 
complex (13,14), and the thrombin-antithrombin (TAT) pair (11,15-17).  A number of 
methods have been employed to determine the number of binding sites and the region(s) 
or residues involved in the interaction of vitronectin with its various ligands.  These 
methods include 1) binding studies using synthetic peptides; 2) experiments with 
cleavage products created via chemical and proteolytic digestion; 3) studies with 
monoclonal antibodies; 4) competition assays; 5) investigations involving recombinant 
expression of vitronectin polypeptides;  6) (photo)affinity labeling; and/or 7) a 
combination of these methods.  The focus of this proposal centers on the recombinant 
expression of polypeptides to localize the vitronectin binding sites involved in the 
interaction of the protein with the thrombin-antithrombin complex.  The polypeptides are 
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further exploited to epitope map a number of acquired monoclonal antibodies to 
vitronectin.           
   
II. Localization and Tissue Distribution 
Vitronectin was first identified in 1967 as a serum spreading factor (18).  Like 
many other plasma proteins, it is synthesized primarily in the liver and generally 
identified, like fibronectin, as an acute phase protein (19).  It circulates in normal plasma 
at concentrations of 200-400 µg/ml (20,21), which constitutes 0.2-0.5% of total plasma 
proteins.  Non-circulating forms of vitronectin are found in the ECM, and low levels of 
vitronectin expression are detected in lung, kidney, sperm, skin, and brain tissue (22,23).   
Circulating vitronectin is primarily monomeric, whereas matrix vitronectin and 
other tissue-associated forms are predominantly multimeric (20,24).  Approximately 
0.8% of the circulating pool of vitronectin is contained within platelets in a rapid 
releasable form (25-27).  Rather than being synthesized by megakaryocytes, platelet 
vitronectin is most likely endocytosed from plasma and incorporated into α-granules (28).  
 
III.  Vitronectin Function 
Vitronectin is diverse in function.  As mentioned previously, it is particularly 
important in the regulation of hemostasis.  In the complex, highly regulated blood 
coagulation cascade (Figure A.1), an injury to a vessel wall initiates a series of events 
that leads to the eventual conversion of the zymogen prothrombin to the serine protease 
thrombin.  Thrombin in turn cleaves soluble fibrinogen into insoluble fibrin.  Together 









































Figure A.1:  The Blood Coagulation Cascade. 
Schematic representing the several steps involved in the proteolytic cleavage of 
zymogens into their active forms that eventually lead to the formation of a hemostatic 
plug.  Inactive prothrombin is converted to active thrombin via Factor Xa and Va.  
Thrombin in turn cleaves soluble fibrinogen to form insoluble fibrin, thus initiating clot 
formation. 
 4
of injury.  Thrombin's proteolytic activity is inhibited by antithrombin, a serine protease 
inhibitor (serpin) that forms an inactive protease-inhibitor complex with thrombin (29).  
The proteoglycan heparin facilitates this complex formation.  Vitronectin plays a pro-
coagulant role by binding heparin, thus neutralizing the ability of heparin to initiate 
thrombin-antithrombin pairing (29,30).  Vitronectin also binds directly to the thrombin-
antithrombin complex and clears the inactivated pair from circulation (16,31,32). 
Plasminogen activators enzymatically cleave precursor plasminogen to form 
active plasmin.  Plasmin is the main protein responsible for the degradation of the fibrin 
network, defined as fibrinolysis (33).  Inhibitors bind and inactivate plasminogen 
activators to regulate the fibrinolytic process.  Vitronectin plays a key role in this process 
by maintaining the inhibitors in their active conformations and localizing them to the clot 
surface.  The serine protease inhibitor PAI-1 is an important example of an inhibitor of 
fibrinolysis that binds vitronectin (9).  Indeed, the vitronectin-PAI-1 interaction can be 
considered one of the most critical functions of vitronectin.  PAI-1 binds plasminogen 
activators to form an inactive protease-inhibitor complex, thus blocking plasmin 
formation (34,35).  PAI-1, however, is intrinsically unstable and converts readily into an 
inactive, latent form (Figure A.2) (36).  Very importantly, vitronectin binds PAI-1 to 
keep it in an active conformation (7,37,38), thus keeping PAI-1 working as an inhibitor 
of the fibrinolytic process.  
The urokinase plasminogen activator receptor (uPAR) is a glycosylphosphatidyl 
inositol (GPI) anchored receptor that has two major ligands—urokinase plasminogen 
activator and vitronectin (39,40).  Urokinase plasminogen activator (uPA) binds uPAR 








Figure A.2:  Structure of Active and Latent PAI-1.   
The 3D structure of the active form of PAI-1 (a.) illustrates features pertinent to the
inhibitory mechanism of proteases by serpins.  Serpins are folded around a large,
central β-sheet (the A sheet) from which protrudes a surface-exposed loop (the
reactive-center loop or RCL).  Within this loop region are the residues recognized as
substrates by the target protease (uPA or tPA), with the reactive center peptide bond
denoted P1-P1'.  Upon attack of the protease, this P1-P1' peptide bond of PAI-1 is
cleaved by nucleophilic attack of the active-site serine, and an acyl-intermediate is
formed.  In contrast to the normal progression of proteolysis, this acyl-intermediate is
extremely long-lived due to a negligible rate of deacylation.  Structural
rearrangements occur so that the two ends of the cleaved loop separate, and the P1
end, with the enzyme covalently coupled, is partially inserted into the central β-sheet.
As such, the protease is inactivated by formation of a 1:1 stable, covalent complex
with the serpin.  PAI-1 is unique among the serpins because it readily relaxes from this
active form (a.) to a latent, inactive form (b.).  As shown, this occurs by insertion of
the RCL into the central β-sheet to contribute a sixth strand to this secondary
structural element.  This refolding is thermodynamically driven, since the latent form
of PAI-1 is more stable. 
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plasminogen to plasmin in the process of fibrinolysis previously described, thus it plays a 
very important role in tissue remodeling; PAI-1 is its major inhibitor (44).  Vitronectin 
can bind both membrane-bound and unbound/soluble uPAR (40,45-49) with the 
interaction stimulated by uPA occupancy of uPAR .  Additionally, uPA/uPAR binding to 
vitronectin has been shown to be controlled by uPAR dimerization in vitro (50).  The 
association of vitronectin with uPAR appears to be partly responsible for spatial 
localization of uPAR on the cell surface (51).  Through its interaction with matrix 
vitronectin, soluble uPAR may still associate with the cell surface and the ECM (52).  
Vitronectin can also bind uPA (11). The uPA and uPAR binding sites on vitronectin are 
distinct from each other .  PAI-1 shares a vitronectin binding site with uPAR and 
competes for vitronectin binding; the binding of PAI-1 and uPAR is mutually exclusive 
(53-55). 
Vitronectin cellular adhesion via uPAR has been observed in monocytes, 
fibroblasts, epithelial, and smooth muscle cells (47,56-59).  Their interaction causes a 
“potent induction” (51) of actin cytoskeleton rearrangement and cell motility (60).  
Experiments demonstrate that uPAR mediated cell spreading on vitronectin necessitates 
integrin activation and function (61).    
Integrins are so named because they “integrate” the cell with the ECM and 
perform receptor functions in cell interactions, as well as signal transduction.  A typical 
integrin consists of an α/β heterodimer and usually binds a number of ligands.  Integrins 
αVß1, α8ß1, αVß3, αIIbß3, αVß5, and αVß8 have all demonstrated binding to the RGD 
sequence of vitronectin (amino acids 45-47) (62).  Vitronectin has shown to be more 
adhesive than fibronectin (63), another common ligand for integrins, and essential for 
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integrin-dependent cellular attachment. The αVß3 integrin is designated as the vitronectin 
receptor (64,65).  Integrin αVß3 has been extensively studied in the context of metastasis 
(62); such research was initiated by a study that found melanoma cells treated with 
antibodies activating this integrin would greatly increase their invasion across the 
reconstructed basal membrane (66).   
To reiterate, vitronectin has a number of functions in the ECM.  In addition to 
uPAR and integrin binding, vitronectin binds collagen (12) and may localize plasminogen 
and PAI-1 to sites of injury in the vessel wall .  Such localization promotes the 
proteolytic events necessary for tissue remodeling.  Because of these multifunctional 
properties of vitronectin in the extracellular matrix, along with interactions of the protein 
with uPAR and integrins, vitronectin is a good target for studies on tumor metastasis and 
angiogenesis, in that it is inherently involved in these processes.   
Vitronectin is also involved in inflammation.  The complement cascade is 
initiated to prevent and protect against the infiltration of foreign bacteria after the body 
suffers an injury.  Complement factor C5 is proteolytically modified to C5b (67), which 
subsequently reacts with C6 and C7, two other complement proteins.  Binding to C7 
creates an amphipathic complex that can insert within the plasma membrane (68).  This 
C5b-7 complex can also react with C8 to form C5b-8 which catalyzes the polymerization 
of complement factor C9.  This membrane attack complex (MAC) cytolytically acts 
through a membrane-penetrating tubule (69).  Vitronectin inhibits the cytolytic activity of 
the MAC, thus protecting neighboring cells from lysis (13).  Vitronectin is also capable 
of binding a hydrophobic site on the C5b-7 complex which prevents its insertion in the 
plasma membrane (70). 
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Zheng, et al. generated a vitronectin knock-out mouse using gene displacement 
(71).  Although the knock-out mice are viable, reproduce, and develop normally, studies 
with these mice indicate that vitronectin is essential for proper thrombus formation.  
Challenging the knock-outs under different pathologies should help to further clarify 
functions of vitronectin.  
 
IV.  Structure of Vitronectin 
Full length human vitronectin has a molecular mass of 72 kDa by analytical 
ultracentrifugation (72).  In vivo, it can exist in either a full length, single-chain form or a 
two-chain cleaved form; cleavage occurs at Arg-379.   The residue at position 381 affects 
the susceptibility of the protein to cleavage; if threonine rather than methionine is present, 
vitronectin is more likely to be cleaved (73).  Such action results in a two-chain form of 
vitronectin:  a 62 kDa heavy chain and a 10 kDa C-terminal light chain.  The two chains 
are linked via a single disulfide bond.  Several different blood proteinases have been 
proposed to be responsible for the Arg379—Ala380 cleavage.  Recently, however, Seger 
and Shaltiel (74) have reported that furin, a serine endoproteinase within the secretory 
pathway of hepatocytes, cleaves the bond selectively. This would thus suggest that the 
conversion of vitronectin to a two-chain form occurs in the liver (prior to secretion), 
rather than in circulation.     
Currently, the structure of full-length, native vitronectin has not been determined.  This 
can be attributed to a number of significant characteristics of vitronectin: 1) its large size 
and conformational lability; 2) extensive post-translational modifications (75) leading to 
sample heterogeneity; 3) the purification of both the single-chain and double-chain form 
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from human serum which are not effectively separated; 4) the hindrance of site-directed 
mutagenic studies due to inefficient recombinant expression systems; and 5) a high 
degree of adhesion to surfaces and itself.  Recently, however, a prediction by Xu et al. 
(76) presents a model for three structural domains of vitronectin (Figure A.3).  Sequence-
structure alignment and domain fold recognition were performed using the threading 
program PROSPECT (Protein Structure Prediction and Evaluation Computer Toolkit).  
Vitronectin sequence was “threaded” through two sets of known structure templates and 
atomic structures were generated using the MODELLER program.  The model 
corroborated a published intra-domain disulfide between C137—C161 (77) and predicts 
the structure of  1) an N-terminal (somatomedin B) domain;  2) a central region with a 
four-bladed β-propeller fold; and 3) a C-terminal heparin-binding domain.  In addition to 
providing invaluable structural information, these predictions help to support evidence 
for the organization of multi-functional vitronectin into these individually folded 
domains, which has been tested and described in the literature.    
 
V.  Domain Organization 
Several studies have been performed to evaluate the multiple functions of 
vitronectin and binding to various target ligands.  From these investigations, a multi-
domain protein model has been described.  The organization of different domains 
provides a broad range of epitopes requisite for the binding of many target ligands.  
Indeed, multi-functional proteins are often found composed of independently folded 
domains linearly arranged with respect to amino acid, and it appears that vitronectin fits 




































Figure A.3: Model for the Three-Dimensional Structure of Vitronectin. 
The N-terminal somatomedin B domain (a), central domain with a four-bladed ß-propeller fold (b), and C-
terminal heparin-binding domain (c) are shown here in their predicted conformations. The color from the 
red to blue shows the sequence order from the N-terminus to the C-terminus. The yellow solid spheres 
indicate cysteines. White spheres (a) show the integrin attachment site; red spheres (b) show glycosylation 
sites (residues 150 and 223); and thin lines (c) show the heparin-binding site. (d) Linear representation of 
the sequence of vitronectin, with blue highlighting corresponding to domains modeled in (a–c), yellow dots 
indicating cysteines, red structures representing carbohydrate attachment sites, and the white arrow 
pointing to the known site of protease cleavage creating the two-chain form. (e) Docking structure between 
the central (blue) and C-terminal (yellow) domains, with cysteines (red lines), presumed heparin-binding 
residues (354–363 in white ribbons), sites susceptible to protease (residues 305, 361, 370, 379 and 383 with 
light blue spheres), and N-linked glycosylation sites (residues 150 and 223 with green spheres).  Predicted 
docking of the N-terminal, central and heparin-binding domains (f), and the predicted structure of each 
domain separately (g) (76).   
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In addition to the computational model, much support for a multi-domain 
organization springs from proteolysis experiments where isolated vitronectin fragments 
retain their ligand binding function.  (Table I summarizes the common vitronectin 
digestion products and their ligand binding activity.)  Vitronectin is rich is arginines and  
lysines, but most of the protein is resistant to cleavage by trypsin-like proteases.  
Vitronectin has two sites that are readily accessible to proteolysis:  1)  an N-terminal 
sequence within residues 44 and 90, and 2) a C-terminal site spanning residues 340-370.  
Within the sequence spanning 340-370, vitronectin can be cleaved by plasmin (78,79), 
thrombin (78), and mast-cell tryptase (Cynthia B. Peterson and David Johnson, 
unpublished observations).  Upon prolonged exposure to plasmin, vitronectin is cleaved 
near the N-terminus at the K88—G89 bond (80).  Trypsin cleaves the protein between R44 
and G45 (81).  A number of potential elastase cleavage sites also exist in vitronectin, but 
elastase only cleaves vitronectin at residues 330 and 383 (79).  Synthetic peptides and 
monoclonal antibodies have also been integral for the assignment of functional domains 
within vitronectin.  Additionally, domain organization was determined through 
sequencing of human and rabbit cDNAs.  The carboxy-terminal of vitronectin shared 
sequence homology with another circulatory protein, hemopexin.   
The complete open reading frame of vitronectin consists of 8 exons encoding 459 
amino acids for the mature protein (exons 2-8), preceded by a 19 amino acid signal 
peptide (exon 1).  Along its linear sequence, vitronectin is organized into four regions 
(Figure A.4) The N-terminal (somatomedin B) domain comprises amino acids 1-44 and 
contains eight cysteines which form four disulfide bonds.  The second region, a  
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Table I:  Ligand Binding Activities of Vitronectin Fragments. 
Treatment  Fragment  Interaction*  References 
Cyanogen Bromide 1-340   + Cells   (82) 
      + Heparin  (23,82,83) 
      + PAI-1   (83) 
      - PAI-1   (23) 
   51-340   - Cells   (82) 
      - Heparin  (82) 
      - PAI-1   (23,82,83) 
      +C5b7   (84) 
340-381 – Cells   (23,82,83) 
+ Heparin  (13,23,82,83) 
+ PAI-1   (83) 
- PAI-1   (23) 
+ C5b7   (13) 
 
Formic Acid  1-51   + PAI-1   (23) 
1-217 + Cells   (82) 
- Heparin  (23,82,85) 
+ PAI-1   (23) 
+ Collagen  (85) 
218-379 – Cells   (82) 
+ Heparin  (23,82,85) 
- PAI-1   (23) 
+ Collagen  (85) 
 
Thrombin  1-306   - Heparin  (38,79) 
      + PAI-1   (38)  
- PAI-1   (79) 
 
Trypsin   1-45   + PAI-1   (81)  
 
Plasmin   1-361   + Cells   (80) 
- Heparin  (86) 
+ PAI-1   (80) 
- PAI-1    (78-80,86) 
+ Plasminogen  (79,86) 
- uPAR   (55) 
   89-361   - Cells   (80) 
      - PAI-1   (80) 
 
Elastase   1-330   - Heparin  (79) 
      - PAI-1   (79) 
 *A number of ligands were tested for interaction with the described fragments.  Positive
interaction is indicated by a “+,” while those fragment-ligands that demonstrated no interaction are












1-44  46-130  131-320 321-459 
Cleavage Site 
(379) 
Heparin Binding Region 
(340-379) Cleavage Site 
(44) 
Integrin Binding Site 
(RGD) 
Figure A.4:  The Linear Organization of Vitronectin. 
Vitronectin is linearly organized into four domains or regions:  an N-terminal (somatomedin B) domain created by
cleavage at residue 44, a connecting region, and two hemopexin domains that share sequence homology to tandem
repeats of the heme-binding protein hemopexin.  Yellow circles denote cysteines residues.  The integrin recognition
sequence (RGD), the heparin binding site, and a second endogenous cleavage site at residue 379 are also noted.  
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connecting region, spans amino acids 45-130 and contains the familiar integrin binding 
sequence Arg-Gly-Asp (RGD). The remaining protein consists of seven hemopexin-type 
repeats, so named because of their sequence homology to the heme-binding protein 
hemopexin.  The first four repeats are considered hemopexin homology domain I (aa 
131-320) and contain four cysteines.  The last three repeats are grouped as hemopexin 
homology domain II (aa 321-459), contain 2 cysteines, and house the site of heparin 
binding.  
It is generally accepted that ligand binding to vitronectin is localized to distinct 
domains or linear epitopes.  With this acceptance comes the possibility that vitronectin 
may interact with more than one ligand simultaneously.  Indeed, several examples exist 
in the literature.   1) Via interactions with both collagen and heparan sulfate 
glycosaminoglycans, vitronectin is incorporated in the ECM (87-89).  2) Matrix 
vitronectin binds to both uPAR and integrin receptors on cells. 3) It can bind to PAI-1 
and plasminogen (8,90,91),  and 4) vitronectin binds glycosaminoglycans concurrently 
with the thrombin-antithrombin (TAT) complex (92).  Elucidation of ligand epitopes is 
important not only for understanding the vitronectin-ligand interaction but also for 
appreciating the multi-functional characteristics of this diversified protein.  
 
i. N-terminal (Somatomedin B) Domain  
 The N-terminal 44 amino acid sequence of vitronectin shares identical sequence 
homology to a reportedly naturally occurring circulating “somatomedin B” plasma 
protein, present in serum at concentrations of 12-14 µg/ml (93).  A separate gene 
encoding somatomedin B has yet to be identified, so it is believed that vitronectin is 
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cleaved by an (as of yet) unidentified protease to release the somatomedin B (SMB) 
domain in vivo (94).  The physiological role of somatomedin B has yet to be elucidated 
and its name now believed to be a misnomer.  It was originally thought to be a member of 
the somatomedin/insulin-like growth factor family, but it was later discovered that the 
growth-promoting activity of somatomedin B was actually due to trace amounts of 
epidermal growth factor in the studies that assigned such activity (95).   
Trypsin proteolysis cleaves the N-terminal (somatomedin B) domain from 
vitronectin in vitro, and even after prolonged protease digestion, the domain sequence 
remains intact.  This suggests a tightly folded domain that renders protease susceptible 
areas inaccessible.  Indeed, 8 of the 14 cysteines in vitronectin lie within this region of 
the protein, forming what can be described as an intradomain disulfide “knot” with all 8 
cysteines participating in disulfide linkages.   
 A PAI-1 binding site has been localized to the N-terminal (SMB) domain by 
Seiffert, et al. (23).  Chemically-derived fragments of vitronectin were shown to compete 
with full length vitronectin for PAI-1 binding.  After direct binding studies, further 
digestion with cyanogen bromide (CNBr) identified the essential binding region as the 6-
kDa N-terminal (somatomedin B) domain.  In addition, monoclonal antibody (mAB) 153, 
which recognizes the N-terminal (somatomedin B) region of vitronectin, was used in a 
competition study with PAI-1 to further verify PAI-1 binding in this region (96).   
Polypeptides of vitronectin were also expressed in E. coli and tested for interaction with 
PAI-1.  Polypeptides containing residues 1-52 and 1-40 bound to PAI-1, but the 1-30 
peptide did not (96).  Two additional studies (38,81) also localize PAI-1 binding to the 
SMB domain using thrombin-cleaved and trypsin-digested vitronectin fragments.  
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 Deng et al. (97) generated chimeras between segments of N-terminal (SMB) 
domains that bound PAI-1 and segments of the N-terminal domain that did not to 
investigate important PAI-1 binding regions.  The results of this study indicated that the 
essential PAI-1- binding determinant was between residues 12 and 30 on vitronectin.  
The importance of proper (SMB) domain folding was also demonstrated in this study.  
Alanine scanning mutagenesis created mutants that were screened for ability to bind and 
stabilize PAI-1.  Results reported that all 8 cysteines and Gly12, Asp22, Leu24, Tyr27, 
Tyr28, and Asp34 were necessary to preserve PAI-1 activity. 
Additionally, Deng et al. (53) demonstrated that mAB 153 inhibited the binding 
of plasminogen activator and urokinase plasminogen activator receptor (uPAR) to 
vitronectin, thus also suggesting the binding sites for these ligands in the (SMB) domain.  
This study also generated synthetic peptides of vitronectin to confirm the localization of 
uPAR binding.  It has also been suggested that the thrombin-antithrombin (TAT) 
complex binds in this region by a study using antibodies recognizing a 6 kDa CNBr 
amino-terminal fragment of vitronectin; the antibodies inhibited the interaction of TAT 
with vitronectin (16).  
 
ii. Integrin Binding Sequence     
At amino acid positions 45-47 lies the familiar integrin recognition motif of Arg-
Gly-Asp (RGD).  The RGD sequence is conserved in a number of other integrin-binding 
ECM proteins including fibronectin, fibrinogen, and von Willebrand Factor (62).  When 
this RGD sequence is selectively mutated (KGD, RAD, RGE) or removed, the ability of 
vitronectin to bind cells is lost, thus making this sequence absolutely necessary for 
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vitronectin-promoted adhesion and spreading of cells via integrins (98-100).  Also, when 
the RGD sequence is removed from vitronectin through thrombolytic cleavage, CNBr 
hydrolysis, or extended plasmin proteolysis, the cell-binding activity of vitronectin is 
weakened (80,82). 
 
iii. Connecting Region 
 The connecting region of vitronectin extends from amino acids 45-130 and 
although it contains no cysteines, it does include sites for a number of modifications.  
Tyrosine residues 56 and 59 are modified by sulfation (101), and asparagine residue 67 is 
involved in N-linked glycosylation (94).  Additionally, vitronectin has been identified as 
a substrate for transglutaminase and factor XIIIA in vitro, with glutamine residues 73, 84, 
86, and 93 believed to be the primary substrates for transaminoglutaminate reactions (77).  
Transglutamination stimulates the formation of higher order vitronectin complexes that 
cannot be dissociated by either SDS or reducing agents.  It is not known whether 
multimerization of vitronectin in vivo is mediated by transaminoglutaminase. 
 Several ligands are proposed to have binding sites within the connecting region, 
including a second binding site for PAI-1.   Studies with Staphylococcus aureus protease 
V8-cleaved vitronectin identified an inhibitory fragment in this region (102).  In the same 
study, a synthetic peptide corresponding to residues 115-121 inhibited PAI-1 binding to 
vitronectin by 50%.  This same peptide also stabilized PAI-1 activity in kinetic assays.   
A phage display synthetic peptide competed against immobilized vitronectin for 
heparin binding, suggesting the localization of a heparin binding site within the 
connecting region (103).  Ishikawa-Sakurai et al. have shown that formic acid-hydrolyzed 
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vitronectin polypeptides containing the connecting regions demonstrate affinity for 
collagen (85).  The use of mAB in competition experiments also supports a collagen 
binding site within this region (104).   
 
iv. Hemopexin Repeats    
 The remaining portion of vitronectin (amino acids 131-459) consists of seven 
“hemopexin repeats” organized into two domains—hemopexin homology domain I and 
hemopexin homology domain II (HPD I and II).  The individual domains of hemopexin 
are comprised of four tandem repeats. The structure of hemopexin is a 4-bladed ß-
propeller fold, with each repeat corresponding to a blade of the propeller.  Vitronectin 
contains seven repeats, one less than the eight repeats requisite for two complete 
hemopexin domains (105).  Like the N-terminal (somatomedin B) domain and the 
connecting region, the hemopexin homology repeats of vitronectin are highly resistant to 
proteolytic cleavage.  Six cysteines are contained in this portion of the protein, two of 
which are reduced and buried (72).  Two additional N-linked sites of glycosylation are 
found at asparagine residues 150 and 223 (94).   
 HPD I extends from residues 131-320 and contains the first four tandem repeats 
representative of a complete hemopexin structure.  HPD II comprises amino acids 321-
459 and contains the remaining three repeats which could result in an incomplete three-
dimensional fold in regards to hemopexin.  HPD II houses the important heparin binding 




v. Heparin Binding Sequence 
 A cluster of basic amino acids (residues 345-379) lies within the second 
hemopexin homology domain and houses the apparent binding site of heparin.  Within 
this region, two motifs are identified that correspond to the heparin-binding consensus 
sequences derived from (other) heparin-binding proteins (106).  Additionally, serine 378 
within this region is phosphorylated in vivo;  in vitro phosphorylation has been 
demonstrated by protein kinase A (107-111).   Mentioned previously, vitronectin 
circulates in both a double and single chain form resulting from proteolytic cleavage 
between arginine 379 and alanine 380 (112).  The charged heparin-binding sequence and 
the residues flanking the sequence exhibit increased susceptibility to proteolytic cleavage 
in vitro, which is in contrast to a majority of the other tightly folded regions of 
vitronectin. 
 In addition to the high degree of similarity between this region and other 
sequences in known heparin-binding proteins, a number of studies have been performed 
on this region to further support a heparin binding site.  CNBr digestion yields a product 
that competes with full-length vitronectin for heparin binding and inhibits the 
anticoagulant acitivity of heparin (82).  Studies reported by Gibson et al. (113) 
demonstrate that heparin binding is significantly reduced upon the incorporation of a 
arginine-reactive probed.  This probe was later localized to a CNBr fragment 
corresponding to residues 341-380.  Further work by this group with recombinant 
polypeptides of the 129 C-terminal amino acids shows that heparin binding affinity of 
this polypeptide is comparable to that of full length vitronectin (114), thus suggesting that 
this region of vitronectin is responsible for heparin binding.  Synthetic peptides and 
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mABs mapping to the heparin binding region inhibit the binding of heparin to this region 
of vitronectin (86).  Plasmin proteolysis within this region hinders the ability of the 
resultant vitronectin to bind heparin (79,86).  In addition, removal of sequences between 
residues 306-370 and 331-383 (via the addition of thrombin and elastase) also 
demonstrates a loss of heparin-binding activity (79).    
A number of other target ligands of vitronectin have been localized to the heparin 
binding region including PAI-1 (78,83,115,116), plasminogen (83),  uPAR (53), 
complement complex (69,117), collagen (85,87), and the thrombin-antithrombin (TAT) 
(118).   Additionally, a number of microorganisms may bind vitronectin at the heparin- 
binding sequence (119-121).  TAT, uPAR, complement complex, and collagen binding 
regions were elucidated using either synthetic peptides or CNBr cleavage products.  In 
these studies, binding of the various ligands to full-length vitronectin was inhibited by the 
peptide or cleavage product.   
More extensive experimentation has been performed to localize the binding sites 
for plasminogen and PAI-1 to this region.  A plasmin cleavage product containing 
vitronectin residues 1-361 retains plasminogen-binding activity (79,86).  The 
plasminogen activity was disrupted by treatment of the peptide with carboxypeptidase 
which suggests the C-terminal of the fragment is involved in the interaction with 
plasminogen.  Kost et al. used a number of overlapping synthetic peptides derived from 
the heparin-binding region of vitronectin to localize the plasminogen binding site to 
residues 340-348 (86).  Further evidence by Preissner supports this localization; 
Stapholococcus V8 protease-cleaved fragments and cathepsin D fragments bound both 
heparin and plasminogen in ligand-blotting assays (91) 
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In other studies by Preissner, it was demonstrated that active or latent PAI-1 binds 
to immobilized synthetic peptides corresponding to the heparin-binding region.  These 
peptides also inhibited vitronectin binding to PAI-1 in microtiter plates (116).  Kost et al. 
used mABs and competitive assays to localize PAI-1 binding to this region of vitronectin 
(86).  The suggestion that PAI-1 and heparin share a binding site on vitronectin was 
further supported by three studies using plasmin proteolyzed vitronectin (78,80,115).   
Plasmin cleaves vitronectin between residues R361 and S362.  Vitronectin cleaved with 
plasmin was unable to bind heparin or PAI-1.  While intact vitronectin formed a PAI-I-
VN complex that could be co-immunoprecipitated using antibodies to PAI-1, elastase- 
and thrombin-cleaved vitronectin did not form such a complex with PAI-1, not surprising 
because these proteases excise the heparin-binding domain (108).  Vitronectin peptides 
were also generated by Preissner et al. through CNBr hydrolysis (83), and these peptides 
demonstrated that both PAI-1 and heparin bind the same 9 kDa fragment that includes the 
carboxy-terminal of vitronectin.  However, Gibson et al (113) provide evidence through 
the use of fluorescent probes that binding determinants for PAI-1 and heparin are not 
shared.   
 
VI.  Considerations 
The evidence suggests almost undoubtedly that vitronectin is organized to support 
multiple domains; multiple domains facilitate the accommodation of several ligand 
binding sites, many of which have been localized and described in the literature.  Upon 
examination of vitronectin activity during different interactions and the epitopes reported, 
a number of discrepancies can be noted.  How are these discrepancies explained? 
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i. Considerations of the Protein 
Perhaps the most obvious thing to consider is that there may be more than one 
binding site on vitronectin for a particular ligand.  For example, a possible resolution for 
the conflicting information concerning PAI-1 binding sites has been suggested by the 
description of two binding regions on vitronectin—one exhibiting high-affinity binding, 
the other demonstrating lower affinity.   The well-defined high affinity binding site is 
located in the SMB domain and the second binding region is suggested at the C-terminal.  
Indeed, a model has emerged that describes PAI-1 binding first to the low affinity 
binding site at the C-terminal which induces a conformational change in the SMB that 
unmasks the high-affinity binding site.  PAI-1/vitronectin complex (either the 1:1 or 2:1 
form) can associate into high order oligomers via the self-association of the vitronectin 
component(s) (122,123).              
A second consideration is the conformational lability of vitronectin. The protein 
can display differential binding activities depending on a specific fold.  This fold-specific 
binding was suggested to be responsible for observations concerning the interaction of 
vitronectin with heparin.  The heparin-binding site was first proposed to be buried within 
the native protein.  A model prevailed suggesting that upon denaturation, the cryptic 
recognition site was exposed and heparin was able to bind (124).   
However, Zhuang et al. found that denaturation of vitronectin is accompanied by 
self association into the multimeric form (125).  A later study determined that heparin 
binding to both monomeric (native) and multimeric (denatured, renatured) vitronectin is 
the same (126).  It is thus concluded that the heparin binding site is fully exposed and not 
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buried within the native fold, and a new model was proposed.  In this model by Peterson 
(Figure A.5), the heparin binding site is fully exposed on the surface and does bind 
heparin.  When vitronectin is refolded, it passes through a partially folded intermediate 
state that has a propensity to aggregate which leads to the formation of multimers.  
Observed enhanced heparin binding can be attributed to the alignment of multiple heparin  
binding sites in the multimeric vitronectin, not the exposition of an encrypted site on a 
monomer.  This example also emphasizes the importance of monomer/multimer 
considerations when studying ligand interactions.  Enhanced interaction may be due to a 
“Velcro-effect” rather than a change in fold.   
Yet another consideration is enzymatic modification.  Studies indicate vitronectin 
is susceptible to intracellular and extracellular proteolysis.  Proteases like plasmin and 
thrombin, which are highly concentrated at injury sites, may cleave vitronectin and affect 
PAI-1 and heparin binding.  In addition, vitronectin contains two sites of endogenous 
proteolytic cleavage, one at residue 44 that releases the SMB domain and one at 379 that 
is responsible for the two chain form of vitronectin.  Endogenous removal of the SMB 
domain demonstrates decreased affinity for PAI-1 (81);  it must be considered that other 
ligand interactions may be affected by endogenous cleavage at these sites. 
Already mentioned are the post-translational modifications of vitronectin, another 
consideration. (Figure A.6 shows sites of post-translational modifications as well as a 
summary of  proposed ligand binding sites within the domain structure of the protein.)  
Protein kinase A phosphorylates vitronectin within the heparin-binding sequence, both in 
vitro and in vivo.  This phosphorylated form of vitronectin may demonstrate altered 

















Figure A.5:  Multimerization Model. 
This model by Peterson suggests that plasma vitronectin is folded with the heparin-binding site exposed
on the surface of the protein.  During refolding, vitronectin passes through a partially folded intermediate
that has a propensity to aggregate.  Multimeric vitronectin results that has heparin-binding sites aligned
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Figure A.6:  Post-translational Modifications and Proposed Ligand Binding Sites Within the    
Domain Organization of Vitronectin. 
As previously described, vitronectin is organized into four domains.  This figure illustrates the sites of
post-translational modifications within each domain.  Also, a number of ligand binding sites have been
proposed in the literature for many of the ligands with which vitronectin interacts. Some proposed
ligand binding regions are represented here. Cysteine residues (C) are noted, as well the integrin
recognition sequence (RGD) and the heparin binding site.   
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sequence of vitronectin (108,109,115,127).  Other modifications could affect ligand 
binding in yet undetermined ways. 
 In summary, conformational lability, multimerization effects, enzymatic 
cleavages, and post-translational modifications can all contribute to discrepancies in data 
if not taken into consideration.  A burden is placed on the researcher to select appropriate 
methods and preparations that will produce results that can be confidently interpreted. 
 
ii. Considerations of Methods 
A number of methods were used to localize ligand binding sites to the different 
domains of vitronectin.  Discrepancies for binding determinants have been encountered, 
especially concerning the binding sites for PAI-1.   In the literature, PAI-I has been 
mapped to three different regions of vitronectin:  the somatomedin B domain (23,81), the 
heparin binding region (86), and residues 115-121 in the connecting region (102).   
Closer examination of the methods employed by different groups reveal possible 
explanations for separate sites for PAI-1 binding and a number of general concerns for 
techniques commonly used to map ligand binding sites.   
Many of the binding sites were determined using fragments of vitronectin 
generated through chemical and proteolytic cleavage, as well as synthetic peptides.  
These methods are susceptible to experimental artifact, and for many experiments, high 
concentrations of the fragments were required to retain function.  One must keep in mind 
that fragments of proteins will not necessarily mimic in vivo interactions (full-length 
proteins will not necessarily, either).   
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Studies with monoclonal antibodies can present problems as well.  Often, if a 
particular monoclonal is found to inhibit or compete for ligand binding to a region of 
vitronectin, that region of vitronectin is assumed to be a site of binding.  Such 
assumptions must be made cautiously.  In characterization of the heparin binding region, 
the monoclonal antibody 8E6, which supposedly mapped to the heparin binding site, was 
used to support the “encrypted site” model previously mentioned. It was later shown by 
Seiffert that 8E6 recognized a different epitope on vitronectin (128).  This antibody 
apparently binds at the N-terminal and disrupts structure at the C-terminus, which 
disrupts heparin binding.  This could be the case for other monoclonals.  Other concerns 
include inconsistent preparation of the proteins involved in the assays and usage of 
different forms of the ligand, including PAI-1 which exists in both an active and latent 
form. 
 
VII. Rationale   
 Much work has been done to localize PAI-1 binding to vitronectin and to 
understand the interaction between the protein and heparin.  But another important ligand 
that binds vitronectin is the thrombin-antithrombin (TAT) complex.  Complex interaction 
with vitronectin has not been characterized extensively, with the regions (and residues) 
on vitronectin involved in binding not conclusively identified.  Using overlapping 
recombinantly expressed polypeptides of vitronectin, the Far Western approach has been 
employed to localize the binding of TAT to vitronectin.  Such localization will help to 
further describe the vitronectin-TAT interaction and provide impetus for further study.  
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These polypeptides are further used to epitope map a number of murine monoclonal 



























 As previously mentioned, we know with confidence that vitronectin binds many 
ligands.  A number of approaches have been used to determine the number of binding 
sites for each ligand and the region(s) of vitronectin involved in the interaction(s).  The 
approach taken in this project involves the expression of bacterial recombinant 
polypeptides of vitronectin.  The polypeptides are tested for interaction with TAT using a 
Far Western approach. 
 The Far Western technique (sometimes referred to as a “West-Western”) is a 
derivation of the traditional antigen-antibody interaction of the Western blot.  Far 
Westerns are commonly used to screen cDNA libraries and/or to study protein-protein 
interactions.  Here, the Far Western technique involves the incubation of a second protein 
of interest with an immobilized protein (electroblotted onto nitrocellulose).  Interaction is 
visualized by detection of an antibody to the second protein.   
 The use of the Far Western technique with recombinant fragments to localize 
ligand binding sites is unique to the body of vitronectin research.  The first target ligand, 
which is the focus of this project, is the thrombin-antithrombin complex.  Thrombin, 
antithrombin, the complex, and interactions with vitronectin will be reviewed in the next 
sections. 
 
i  Thrombin 
Thrombin has many diverse functions in the body, it is the ultimate activation 
product of the coagulation cascade.   Upon injury, the blood coagulation cascade works 
through a series of enzymatic cleavages that activate sequential “clotting factors” that can 
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in turn cleave the next factor until finally soluble fibrinogen is cleaved by thrombin into 
insoluble fibrin. Thrombin serves as a regulator of the coagulation process through both 
stimulatory and inhibitory feedback mechanisms.  It has thus been a popular target for 
anticoagulant drug therapy (129).   
 Thrombin is a serine protease that recognizes particular sequences and catalyzes 
the hydrolysis of arginine-glycine peptide bonds. After the peptide cleavage of 
fibrinogen, fibrin monomers are left with a specific surface charge pattern that promotes 
their aggregation, and this clustering together forms a fibrous blood clot (130,131).  
Thrombin has also been shown to trigger platelet aggregation and catalyze the activation 
of other blood clotting factors V, VIII, and XIII (132).   
 Human blood plasma contains approximately 40-50 mg/L of thrombin, and such a 
concentration is required for proper blood clotting to occur efficiently.  Thrombin is 
activated by the cleavage of its zymogen prothrombin by factor Xa and factor Va.  
Thrombin’s activity is controlled by negative regulators antithrombin III and hirudin, 
both of which function by binding to thrombin’s active site. 
 Thrombin shares structural homology to serine proteases trypsin and 
chymotrypsin.  Thrombin is a glycoprotein formed by two disulfide-linked peptide chains 
of 36 and 259 amino acids.  Three sites of interaction have been identified on the protein, 
the first of which is the negatively charged catalytic site that confers thrombin’s serine 
protease activity and contains the familiar catalytic triad.  On thrombin, these residues 
include histidine 43, aspartic acid 99, and serine 205 (133). 
 The other two sites of interaction are positively charged and named exosite 1 and 
exosite 2.  Exosite 1 borders the catalytic site and binds substrate (fibrinogen or thrombin 
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receptor).  On the enzyme surface, exosite 2 is located proximal to exosite 1 and 
bindsinhibitor antithrombin III responsible for thrombin’s inactivation (134-136).  
Exosite 1 also binds Factor V and Factor VIII, while exosite 2 contains the binding site 
for heparin and thought to be involved in interaction with Factor V and Factor VIII 
(137,138).  Thrombin also interacts with fibrin at either exosite 1 or exosite 2 in a manner 
dependent on whether heparin is present or absent, and then the concentration of heparin 
in the environment if heparin is indeed present.  But in any binding event, thrombin 
remains active due to fibrin binding at a site distinct from the catalytic site on thrombin 
(139-141).  
 Fibrinolysis is the process of clot dissolution, thus thrombin is usually thought of 
as an inhibitor of fibrinolysis.  Interestingly, however, thrombin also demonstrates 
stimulatory effects on the process. First, thrombin is a chemoattractant for neutrophils; 
neutrophils have demonstrated a role in fibrin clot degradation (142).  Second, thrombin 
releases plasminogen activators from endothelial cells (143).  These plasminogen 
activators generate plasmin, a key initiator of fibrinolysis and inactivator of prothrombin.  
Thrombin’s capacity to both inhibit and enhance fibrinolysis demonstrates yet again its 
vital role in hemostasis and the fine balance between clot formation and clot dissolution.  
Disruption of this fine balance leads to either excessive hemorrhage or excessive 
coagulation, conditions that can be potentially fatal. 
 As previously mentioned, thrombin is a chemoattractant for neutrophils and 
monocytes.  Due to this association, thrombin is also involved in inflammation.  At the 
sites of an injury, thrombin concentrates, inducing these cells to gather and carry out their 
phagocytic role to protect against potential bacterial infection (144,145).   
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 Human α-thrombin is composed of two disulfide-linked chains—a 36 amino acid 
long A chain and a 259 amino acid long B chain (146).  ß and γ-thrombin result from the 
limited trypsin proteolysis of α-thrombin’s B chain (147).  ß-thrombin is formed by a 
cleavage at either Arg75—Tyr76 and/or Arg77—Asp78 whereas γ-thrombin has an 
additional cleavage at Lys149—Gly150 (148).  γ-thromin consists of three polypeptide 
segments that are non-covalently associated (149).  Each polypeptide contains one of the 
catalytic triad residues:  Asp-99 is on the A-B3 chain, His-43 is on the B1 chain, and Ser-
205 is on the B4 chain (150).  Significantly, when α-thrombin is cleaved to create γ-
thrombin, clotting activity is either lost or very low, although enzyme activity is retained 
(149,150).  This is explained by disruption of the active site and also an upset of the 
fibrin(ogen) recognition site on γ-thrombin (151).   
 γ-thrombin does bind to antithrombin, but at a reportedly lower rate compared to 
α-thrombin (152).  Electron spin resonance studies indicate that contained within the 
active site of γ-thrombin is a hydrophobic region not present in α-thrombin (153).  This 
altered active site of γ-thrombin may be responsible for findings that revealed a much 
tighter binding of γ-thrombin to vitronectin compared to α-thrombin.  Additionally, it was 
suggested that the α-thrombin component of thrombin-antithrombin was responsible for 
interaction with vitronectin, probably through a region exposed on γ-thrombin (11).   
 
ii.  Antithrombin  
 Antithrombin is a 432 amino acid glycoprotein that plays an important role in the 
regulation of blood clotting (154).  In plasma, antithrombin is the major inhibitor of 
coagulation proteases such as thrombin, Factor Xa, and Factor IXa (155-158).  
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Specifically, antithrombin is a serine protease inhibitor (serpin) (159).  Antithrombin 
deficiencies disrupt hemostasis and can lead to venous thromboses, thus demonstrating 
the important role it plays in maintaining the fine balance between abnormal clotting 
extremes.  
 Antithrombin shares structural homology with α1-proteinase inhibitor, PAI-1, 
heparin cofactor II, and α1-antichymotrypsin--other protease inhibitors (35).  It contains 
three disulfide bonds and four sites of glycosylation (154).  Two X-ray structures of 
antithrombin have been acquired and studied—an intact form and an inactive, cleaved 
form (160,161).  Intact antithrombin possesses two prominent features: 1) a five-stranded 
ß-sheet, the A sheet and 2) a large exposed loop containing the reactive bond (Arg 393—
Ser-394).  Inactive antithrombin is cleaved near the reactive bond, and the N-terminal 
portion of the reactive loop is inserted as a middle strand in the A ß-sheet.     
 One of antithrombin’s most physiologically critical targets is thrombin.  
Antithrombin binds thrombin in a 1:1 stoichiometric ratio whereby thrombin is 
inactivated in a two-step process.  After the formation of an initial “encounter” complex, 
a conformational change occurs to form a stable serpin-enzyme pair (162-167).  Enzyme 
inactivation is initiated upon recognition by the enzyme of antithrombin’s reactive bond 
(168-170).  Antithrombin residue Arg-393 is essential for this recognition (171-173).  On 
thrombin, the serine of the active site (174) and Trp-60 (175,176) are required for proper 
interaction with antithrombin.  It is believed that thrombin attacks the reactive bond of 
the fully exposed loop as in regular substrate binding.  When this happens, the loop with 
thrombin bound folds into the A sheet of antithrombin and this insertion traps the enzyme 
in a stable complex with inhibitor whereby the enzyme is inactivated (174,177-180).  
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 Heparin is a strongly negatively charged glycosaminoglycan that greatly 
accelerates the rate of inhibition of thrombin (and other clotting proteases) by 
antithrombin.  Indeed, the thrombin-antithrombin pairing rate increases 2000-4000 fold in 
the presence of optimal concentrations of heparin (181-184).  Heparin confers its effect 
by first binding to antithrombin (182,185).  Positively charged residues on antithrombin 
recognize a specific pentasaccharide sequence of heparin (186-190), and upon binding, a 
conformational change takes place in antithrombin (Figure B.1).  It is then believed that 
thrombin non-specifically binds the same heparin chain at any number of sites along the 
polysaccharide (183,191).  Thrombin travels down the chain and meets the inhibitor, 
where the two interact.  Serpin-enzyme complex formation results in a greatly diminished 
affinity for heparin (185,192).  Thus, heparin quickly dissociates, leaving it free to bind 
another antithrombin molecule.   
 
iii.  Interactions of the Complex with Vitronectin 
 Vitronectin interacts with the thrombin-antithrombin (TAT) pair to form a ternary 
complex (17,20).  In fact, most TAT found in human serum is complexed with 
vitronectin (31,118). The association of vitronectin with TAT is important for a number 
of reasons.  1) Vitronectin confers its heparin-binding (15) and cell-binding (193) 
properties to the TAT pair when the two components are bound.  2) Studies indicate a 
conformational change in plasma vitronectin upon binding of TAT (15). 3) It has been 
speculated that ternary complex formation is the primary mechanism by which 





















Figure B.1:  Vitronectin Association with TAT and Heparin. 
This schematic represents the heparin-enhanced association of thrombin with its 
inhibitor antithrombin.  Vitronectin binds not only the complex, but the molecule that
facilitates complex formation.  It is believed that once vitronectin binds TAT, the
ternary complex is cleared from circulation. 
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suggested that vitronectin binding to TAT is largely responsible for the clearance of the 
complex from circulation (92,194,195).  
Previous work from this laboratory has contributed significantly to the 
understanding of the interaction between vitronectin and TAT.  These studies have shown 
that the thrombin component of TAT is responsible for vitronectin binding, in that 
thrombin alone can bind vitronectin, but antithrombin is only detected bound to 
vitronectin when it is complexed with thrombin.  Additionally, high performance liquid 
chromatography (HPLC) experiments demonstrated that VN-T-AT complexes lead to 
vitronectin multimerization over time.  
 The nature of the interaction between vitronectin and TAT has been reported to be 
a covalent interaction formed by a disulfide bond (11,15,112), catalyzed by protein 
disulfide isomerase (PDI) (196).  Neither thrombin nor antithrombin has free sulfhydryl 
groups, thus a thiol-disulfide exchange is suggested, with the thiol(s) being contributed 
by vitronectin (112).  In contrast, additional work from this laboratory reports evidence 
that the interaction is not disulfide mediated, but is rather an ionic interaction; in the 
presence of iodoacetamide, ELISA experiments demonstrated that VN-T-AT complexes 
were not affected.   
Other subjects of speculation and study concerning the vitronectin-TAT 
interaction are 1) how many binding sites does vitronectin contain for the thrombin-
antithrombin pair and 2) what regions of the protein are involved in the interaction with 
TAT?    This laboratory has demonstrated that the binding site for the thrombin-
anithrombin complex is separate from the PAI-1 binding site.  It has also been suggested 
through monoclonal antibody experimentation that the amino portion of vitronectin is 
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involved in ternary complex formation (16), although the interaction is proposed to be 
disulfide-mediated, which our laboratory disputes.  Early reports speculated that the 
heparin binding region of vitronectin could be a potential site for the vitronectin-TAT 
interaction (124,181). The focus of the research presented here is to use recombinantly 
expressed fragments of vitronectin to localize the binding region(s) for thrombin-
antithrombin.  The interaction will be detected using a Far Western technique.   
 
II. Experimental Procedures 
i.  Proteins, Antibodies, and Protease Inhibitors 
The proteins, antibodies, and protease inhibitors used throughout this study were 
obtained as follows.  Native, monomeric vitronectin was purified from human blood 
plasma using a modified protocol of the method developed by Dahlback and Podack 
(112).  Human α-thrombin was purchased from Haematologic Technologies, Inc. and 
human antithrombin III was obtained from the American Red Cross (manufactured by 
Baxter Healthcare Corporation).  Polyclonal antibodies to human α-thrombin and human 
antithrombin III were also purchased from Haematologic Technologies, Inc.  Monoclonal 
anti-polyhistidine clone his-1 (peroxidase conjugated) was purchased from Sigma.  HRP-
conjugated secondary antibodies were purchased from Vector labs (anti-mouse and anti-
goat) and Santa Cruz Biotechnology (anti-sheep).  All protein standards were 
Kaleidoscope protein or polypeptide standards purchased from Bio-Rad.  Protease 




ii.  Transformation into Expression Cells 
cDNAs encoding eight overlapping polypeptides of vitronectin 100 amino acids 
in length (aa 1-100, 51-150, 101-200, 151-250, 201-300, 251-350, 301-400, and 351-459) 
were obtained from D. Seiffert (DuPont Merck Research Laboratories).  Figure B.2 
demonstrates the domains of vitronectin each polypeptide spans.  These were cloned into  
the multiple cloning site of  pET-15b (Novagen) which carries an N-terminal His-Tag 
sequence.  The recombinant plasmids were transformed into BL21DE3pLysS E. coli 
(Novagen) according to company protocol. 
 
iii.  Directional Cloning of aa 251-350 and 301-400 
It was determined from Christine Schar’s previous work that the original DNA for 
polypeptide 251-350 (obtained from D. Seiffert) contained mutations at positions ****  
Christine worked to correct the sequence and cloned the corrected gene into the yeast 
vector pAS2-1 (Clonetech) to pursue yeast two-hybrid studies.   
     For the research presented here, the 251-350 polypeptide cDNA was cloned back 
into pET15b.  pAS2-1/251-350 was transformed into DH5α E. coli.  The recombinant 
plasmid was purified using a midiprep kit (Qiagen).  The 251-350 cDNA was excised 
using the restriction enzymes BamHI and NdeI (part of the multiple cloning sites in both 
plasmids of interest), available from Fisher Scientific.  251-350 cDNA was purified from 
1.5% agarose gel electrophoresis using Qiagen’s QiaQuick Gel Extraction Kit.  pET15b 
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Figure B.2:  Linear Organization and Corresponding 100 Amino Acid Polypeptides. 
Vitronectin is (linearly) organized into 4 regions.  The 14 cysteines are noted, as is the familiar integrin binding recognition
sequence (RGD) at the end of the  somatomedin B region, and the heparin-binding site in hemopexin domain II. Overlapping
polypeptides 100 amino acids in length were engineered and cloned into the pET expression system.  They are shown here to
give a general idea as to which region(s) each encompasses. 
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reaction was performed using Invitrogen’s T4 DNA ligase according to company 
protocol.  The reaction was transformed into DH5α cells and plated on LB/amp.  
Colonies were grown overnight in 2 ml TB/amp, midiprepped (Qiagen), and a double 
digest was performed to confirm insert.  Upon confirmation of insert (visualization of  
~300 bp band), plasmid/insert was transformed into BL21(DE3)pLysS E. coli according 
to company protocol.   
 Upon DNA sequence analysis of the 301-400 recombinant, it was determined that 
the lac operator harbored a mutation.  To correct the problem and obtain a functional 
operator, the 301-400 cDNA was excised from the mutated plasmid again using the 
restriction enzymes BamHI and NdeI.  301-400 was purified from 1.5% agarose gel 
electophoresis using Qiagen’s QiaQuick Gel Extraction Kit.  The gene was ligated into 
the previously purified pET15b using Invitrogen’s T4 DNA ligase according to company 
protocol and plated as described above.  Confirmation of insert was visualized using 
agarose gel electrophoresis and DNA sequence analysis demonstrated a corrected lac 
operator.   
 
iv.  Small-scale Inductions 
Isolated colonies from the previously mentioned transformations were selected for 
overnight growth (37oC with shaking) in 2.0 ml of Terrific broth (TB available from 
Gibco) containing ampicillin (50µg/ml) and chloramphenicol (34µg/ml).  Duplicate 
cultures of each colony were prepared and grown to mid-log phase and protein 
expression was induced in one of the duplicate cultures with 1.0mM IPTG (Sigma) and 
grown for another 4 hours.  All cultures were harvested using centrifugation (13,000 rpm 
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5 min.) and the supernatant was decanted.  Cells were resuspended in 50 µl 2X sample 
loading dye, boiled, and analyzed using 15% SDS PAGE.  Expression was assayed by 
immunoblotting to nitrocellulose at 20V for 20 minutes.  Membranes were blocked for 1 
hour in 10% dry milk/PBS.  After washing, membranes were incubated with an anti-
polyhistidine antibody (peroxidase conjugated) at a dilution of 1:2000.  Expression was 
detected upon addition of substrate (12µl H202, 30ml PBS, 6 ml 4-chloro-1-naphthol).   
 
 
v.  Large-scale Inductions/expression 
2.0 L of enriched media (47.0 g/L TB, 5.0 g/L YNB (Difco), 4.0 ml/L glycerol, 
50µg/ml amp, 34µg/ml chlor, pH 7.2) was prepared and inoculated with 100 ml of ~2.5 
hour culture (TB/amp/chlor).  Cells were allowed to grow with shaking at 37oC till OD600 
indicated log phase.  Protein expression was induced with 1.0 mM IPTG (Sigma) and 
cells allowed to grow for another 8-12 hours.  Cells were harvested by centrifugation 
(10,000 rpm at 4oC in Beckman JA-10 rotor for 30 minutes) and stored in -20oC freezer 
until purification. 
 
vi.  Metal-chelating Affinity Chromatography 
2.0 L cells were resuspended in 160 ml resuspension buffer (5mM imidazole, 
40mM Tris-HCl, 500mM NaCl, leupeptin, Pefabloc, Pepstatin A, pH 7.9).  Cells were 
lysed using sonication.  Sonication product was separated using centrifugation (10,000 
rpm in Beckman JA-10 for 30 min., 4oC).  Supernatant was poured off and reserved; 30 
µl of the supernatant was analyzed by 15% SDS PAGE.  If the polypeptide was contained 
 43
in the pellet portion, 60 ml of solubilization buffer (5mM imidazole, 40mM Tris-HCl, 
500mM NaCl, 6.0 M urea, protease inhibitor cocktail, pH 7.9) was added to the 
sonication pellet and the pellet resuspended.  Cellular debris was separated from the 
solubilized pellet by centrifugation (10,000 rpm in Beckman JA-10 rotor, 40 min., 4oC) 
and the supernatant reserved.   
     Soluble or urea-solubilized polypeptide sample was loaded on an equilibrated 
Chelating Sepharose® Affinity column (Pharmacia) charged with 100mM NiSO4 at a 
flow rate of 1.0 ml/min and 3.0 ml fractions were collected.  Wash buffer (16 mM 
imidazole) was passed over the column till A280 readings were ~0.00.  Protein was step-
wise eluted with 75 mM, 150 mM, and 300 mM imidazole buffer.  Fractions were 
analyzed on 15% SDS-PAGE and Western blotted with fractions containing polypeptide 
detected using an anti-polyhistidine antibody.  Protein concentrations were determined 
using the Bradford Assay (reagents available from Bio-Rad).  Polypeptide 101-200 
fractions were concentrated using an Amicon (10,000 molecular weight cut-off) 4.0 ml 
centrifuge concentrator.  3.0 ml of sample was loaded and centrifuged 30 minutes in a 
swinging bucket centrifuge (4000 rpm, 4oC).   
 
vii.  Far Western Technique  
1.  Full-length Vitronectin  
Either 3 or 5 µg native vitronectin in PBS was loaded on a 10 % gel and SDS-
PAGE was performed.  Protein in the gel was transferred to nitrocellulose at 20V for 20 
minutes, blocked for 1 hour in 10% dry milk/PBS, and then incubated overnight with 
shaking at 4oC with 100 µl thrombin-antithrombin complex in 30 ml PBS solution 
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(complex prepared by incubating 400 ug/ml thrombin with 1.5 mg/ml antithrombin for 
one hour to form a stable complex).  After washing with PBS/0.1% Tween, the 
membrane was divided and incubated with shaking for one hour at room temperature 
with an antibody raised against either thrombin or antithrombin. Each membrane was 
washed again with PBS/Tween and peroxidase-conjugated secondary antibodies 
(thrombin -- anti-sheep; antithrombin -- anti-goat) were allowed to bind for one hour with 
shaking at room temperature.  The membrane was developed upon addition of substrate.   
 
2.  Polypeptide Fragments of Vitronectin 
 Approximately 20µg of each pure polypeptide was loaded into 15% SDS-PAGE.  
Two different Western blot protocols were employed with the polypeptides involving two 
different transfers.  In some experiments, polypeptides were transferred to nitrocellulose 
at 20V for 20 minutes using a BioRad Semi-dry Blotter and the same protocol was 
followed as for the native, full-length vitronectin.  Alternatively, some polypeptide gels 
were transferred to Immobilon™ (Millipore) at 24V for 30 minutes in a submerged gel 
transfer apparatus.  The membranes were blocked for 1 hour in 5% dry milk in TBS/0.1% 
Tween.  The membranes were then incubated overnight at 4oC with the thrombin-
antithrombin complex (prepared as described above) in TBS/Tween.  The membrane was 
washed 3X for 10 minutes in TBS/Tween.  Membranes were incubated with either an 
anti-thrombin or anti-antithrombin antibody for 40 minutes in 2.5% dry milk in 
TBS/Tween.  Again, the membranes were washed and appropriate peroxidase conjugated 
secondary antibodies were allowed to bind for 40 minutes.  The membranes were washed 
as described and then bathed in a 1:1 solution of SuperSignal® Chemiluminescent 
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Substrate ULTRA Stable Peroxide Solution and Chemiluminescent Luminol/Enhancer 
Solution (Pierce) for 1 minute.  The membranes were exposed on a film sheet for 5 
minutes and developed in the dark room. 
 
III. Results 
i. Cloning of 251-350 and 301-400  
 The cDNA encoding polypeptide 251-350 obtained by our laboratory included 
mutations that were corrected by another member of our lab and cloned into a yeast 
vector.  For expression in the pET system, it was essential that the corrected cDNA 
sequence be cloned into pET15b.  Figure B.3a is a schematic representing the cloning 
procedure.  The cDNA was excised by a double digest with BamHI/NdeI, which would 
also linearize the plasmid.  After successful purification of cDNA 251-350 and pET15b 
from an agarose gel, T4 DNA ligase was used to ligate the cDNA into the plasmid and 
the reaction was plated. Colonies were analyzed by agarose gel electrophoresis and as is 
obvious from the gel picture in Figure B.3b, a successful clone resulted.   
 The cDNA encoding polypeptide 301-400 was originally in pET15b and the 
cDNA was shown to be correct by DNA sequence analysis, yet no polypeptide was 
expressed when transformed into BL21(DE3)pLysS cells.  Upon sequence analysis of the 
promoter region, a mutation was found in the lac operator, which was believed to be the 
culprit of no expression. Thus the cDNA was excised and purified from the deficient 
plasmid and cloned in a similar procedure as 251-350 into the already successfully 
purified pET15b.  After several attempts, a successful ligation was obtained, seen in 
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Figure B.3:  Cloning of 251-350. 
a. Schematice representing the cloning strategy for 251-350.  cDNA was excised from the yeast plasmid
pAS2-1 using restriction ezymes BamHI and NdeI.  It ws then ligated into the expression plasmid pET15b
which contains an inducible T7 promoter and confers ampicillin resistance. 
b. A 1.5% agarose gel picture of double digested recombinant plasmid.  After the cDNA was transformed into
DH5α cells, the recombinant was purified, double-digested with BamHI/NdeI and analyzed by
























Figure B.4:  Agarose Gel Picture of 301-400. 
cDNA coding for polypeptide 301-400 was cloned into pET15b, double
digested with BamHI/NdeI and analyzed by agarose gel electorphoresis.
The 301-400 cDNA does appear around bp 300, but subsequent attempts
to express this polypeptide by transformation into BL21DE3pLysS cells







ii. Seven of the Polypeptides Were Successfully Expressed 
 To express the polypeptides using the pET expression system, recombinant 
plasmids were transformed into BL21(DE3)pLysS E. coli cells.  This strain was selected 
because of its successful history for inducible expression of protein/polypeptides in pET 
plasmids, the chloramphenicol selection capability, and because this strain codes for 
lysosyme, assisting in efficient lysis of cells when purifying a protein of interest.  Before 
the polypeptides were expressed on a large scale, transformants were screened for 
expression on a small scale.  4-6 colonies were selected and grown in 2.0 ml of media 
and induced with 1.0mM IPTG.  Expression was successfully achieved for seven of the 
eight polypeptides: 1-100, 51-150, 101-200, 151-251, 201-300, 251-350, and 351-459, 
shown in Figure B.5, which does include the new 251-350 recombinant. The colony from 
each recombinant polypeptide that demonstrated the best expression (by visual 
assessment) was selected for growth/expression on a large scale in 2.0 L as described.  
Expression was detected using an antibody to the His-tag at the N-terminal of the 
expressed polypeptide.   
Small scale expression of the polypeptides was performed multiple times 
throughout the course of this project.  Expression levels of each polypeptide were 
somewhat variable from one transformation to another, but each demonstrated a (general) 
repeatable level of expression in comparison to the other polypeptides.  For example, 
polypeptides 201-300 and 351-459 consistently expressed at higher levels than either 1-
100 or 51-150.   Inconsistencies in expression are most easily explained by loading 
variabilities.  Cells are grown in slightly different conditions and post-induction growth 
times do vary for individual induction studies.  It is very difficult to assess the  
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 Figure B.5:  Expression of Overlapping 100aa Polypeptides 
BL21(DE3)pLysS cells containing the recombinant plasmids were induced
to express using 1.0mM IPTG.  Crude extracts were loaded on 15% SDS
PAGE and transferred to nitrocellulose.  Expression was detected using an
anti-His tag antibody and Western blots are pictured here.  Expression was
achieved for all the polypeptides except 301-400.  The newly cloned 251-










concentration of the target polypeptide for each experiment, so a fixed microliter amount 
is loaded and inevitably variable expression levels are detected. 
Even after successfully cloning 301-400, multiple attempts to express the 
polypeptide failed.  When the recombinant plasmid was digested with BamHI/NdeI, an 
“insert” band was visualized by gel electrophoresis.  DNA sequence analysis shows   
correct promoter sequence, and the cells supposedly containing the recombinant plasmids 
are viable.  But this recombinant continues to resist expression. 
 
iii.  Purification Was Achieved for Seven Polypeptides 
To exploit the N-terminal His-tag on each expressed polypeptide, nickel affinity 
chromatography was selected to purify the recombinants. Centrifuged cells were 
resuspended and the cells were lysed by sonication.  Upon Western analysis, polypeptides 
1-100 and 51-150 were found to be present primarily in the “soluble” supernatant, thus 
the chromatography described was conducted in the absence of urea.  Polypeptides 101-
200, 151-250, 201-300, 251-350, and 351-459 were resolubilized in 6.0 M urea buffer 
and further centrifuged to separate cellular debris.  Polypeptide presence was confirmed 
by SDS-PAGE/Western blot in the urea-solubilized sonication pellet and the 
chromatography performed for these polypeptides included buffers containing 6.0 M 
urea.  Affinity chromatography was performed at 4oC to hinder degradation per company 
suggestion.  Polypeptide samples were loaded and washed at a flow rate of 1.0 ml/min 
and 3.0 ml fractions were collected and monitored at 280nm till the absorbance was close 
to 0.0.   
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First attempts at purification with polypeptide 151-250 (found to be a high-yield 
recombinant compared to the other polypeptides) employed a protocol with only one 
elution step with 300 mM imidazole.  This resulted in a polypeptide in solution with 
several contaminants.  Subsequent purifications were performed with a step-wise elution 
of 75, 150, and finally 300 mM imidazole.  This yielded much purer polypeptides. SDS-
PAGE gels for the purification of each polypeptide are shown in Figure B.6.  Protein  
concentrations for the elution fractions with highest absorbance (280 nm) were 
determined using the Bradford Assay, the values of which are listed in Table II.  The 
expression of 101-200 was low compared to other polypeptides, thus a 3.0 ml fraction of 
101-200 was concentrated down to 1.0 ml using an Amicon centrifuge concentrator.     
These polypeptides tend to be susceptible to degradation.  It was observed that 
even 4-5 days after purification, the concentration of a particular polypeptide was 
dramatically reduced, probably due to protease degradation.  Because of this observation, 
a portion of all the eluted polypeptides was immediately reserved, mixed 1:1 with 
reducing sample loading buffer, boiled 5 minutes and frozen in the -80oC storage freezer.  
Figure B.7 is a 15% SDS-PAGE gel picture of the seven purified polypeptides, along 
with relative molecular weight values.    
 
iv. Far Western Conditions Were Optimized   
To determine if this assay could feasibly be used with the protein components 
involved and also to determine effective Far Western conditions to eventually use in 
experiments with the polypeptides, a series of Far Western blots was performed with full-
length vitronectin.  Different amounts of vitronectin—0.5µg, 1.0µg, 2.0µg, 3.0µg, 5.0 µg, 
 52
 
86 87 88 103 115 116 117 
1-100 51-150
- 98 100 116 117 96 97 98 99
101-200 151-250 
+ 77 80 83 85 86 87 88 89104 105 106 107
201-300 251-350 





Figure B.6:  SDS-PAGE of Polypeptide Purifications.  
Original supernatants and fractions from different steps of the purification process
were analyzed by SDS-PAGE for each of the polypeptides and gel pictures are
presented here.  Purification was achieved using nickel affinity chromatography.
The red squares indicate the polypeptide of interest in each gel picture.  Relative
concentrations of pure polypeptides in the noted fractions (red) were assayed
using the Bradford method and a summary is reported in Table II.   
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Table II:  Relative Concentrations of Purified Polypeptides. 
Polypeptide  Fraction #   Concentration (µg/ml)*  
1-100   86    97    
   87    348 
   88    176 
   103    211 
 
51-150   115    71 
   116    212 
   117    81 
 
101-200 98    5    
100    2 
116    19 
117    53 
 
151-250  96    63 
   97    1034 
   98    259 
   99    64 
 
201-300 104    378    
105    457 
106    106 
107    23 
 
251-350  77    167 
80    258 
83    310 
85    374 
86    2459 
87    2763 
88    1432 
89    562 
 
351-459 80    1323    
81    924 
82    421 
83    311 
 










Lane     Polypeptide    Molecular Weight 
1        1-100               14,000 
2       51-150              13,450 
3       101-200            13,500 
4       151-250            14,000 
5       201-300            14,500  
6       251-350            14,400 
7       351-459            15,600 




Figure B.7:  Purified Polypeptides of Vitronectin. 
This is a 15% SDS-PAGE gel picture of the purified polypeptides.  In addition, their
relative molecular weights are listed; these weights include the N-terminal his-tag.
Approximately 10µg total protein was loaded in each lane.  Full length vitronectin





and 10µg—were loaded on 10% SDS-PAGE and then transferred to nitrocellulose.  
Blocking conditions were consistently 10% dry milk in PBS.  Different 
concentrations/molarities of TAT complex were incubated with the membranes and 
allowed to bind at room temperature for 1 hour or overnight at 4oC to determine the better 
binding conditions.  After incubation with the complex, the membranes were allowed to  
bind primary antibodies to thrombin and antithrombin (separate membranes).  Dilutions 
of the primaries were varied in these optimization experiments to assay both 1:2000 and 
1:1000 dilutions.  Secondary peroxidase-conjugated antibodies were consistently 1:2000 
dilutions.  From the optimization experiments (Figure B.8), the best conditions were 
determined to be 3µg protein (or comparable ratio of polypeptide), overnight binding of 
the complex (200 µl in 30 ml 1% dry milk/PBS) at 4oC, and 1:2000 dilution of the 
primaries.  Such conditions were necessary to elicit a visual colormetric signal.  A 
positive result also supported the usage of such a method to study interaction between 
vitronectin (or polypeptides) and the thrombin-antithrombin complex. 
 
v.  The TAT Complex Localizes to Two Regions on Vitronectin 
 With an optimized protocol, Far Western experiments were attempted with the 
purified polypeptides. Approximately 10-20µg total polypeptide were loaded on 15% 
SDS-PAGE with appropriate controls (full-length vitronectin and either thrombin or 
antithrombin).   The conditions used to produce a positive signal with full-length 
vitronectin initially did not give a positive signal with the polypeptides.   Vitronectin was 
serving as a positive control and it was visualized on each blot, but the polypeptides 
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Figure B.8:  Far Western Results for Native Vitronectin and TAT Interaction. 
3µg and 5µg of vitronectin was loaded on 10% SDS-PAGE and transferred to
nitrocellulose.  The membrane was blocked for 1 hour in 10% dry milk in PBS and
then allowed to incubate with the thrombin-antithrombin complex overnight at 4oC.
After washing, the membranes were allowed to incubate with either anti-
antithrombin (a.) or anti-thrombin (b.) primary antibodies diluted 1:2000.
Peroxidase-conjugated secondary antibodies were allowed to bind and then









varying one condition:  greater amount of total polypeptide was loaded, blocking 
conditions were reduced to 5% dry milk in PBS for 45 minutes instead of an hour, 
dilution of the primary antibody (to both thrombin and antithrombin) was increased to 
1:1000.  Still, an interaction was never indicated with the chromagenic development 
method routinely employed in this laboratory. 
Seeking a more sensitive detection method, Far Western experiments were 
performed employing chemiluninescent development techniques.  Approximately 10µg  
total of each polypeptide was loaded on 10% SDS-PAGE and transferred to Immobilon™ 
(Millipore) via a submerged transfer apparatus.  The blot was blocked 40 minutes in 5% 
dry milk TBS/Tween and allowed to incubate with the complex (50 µl 400µg/ml 
thrombin:50µl 1.5 mg/ml antithrombin in 30 ml 2.5% dry milk TBS/Tween) overnight at 
4oC.  After careful washing for 30 minutes total, primary antibodies were diluted 
1:25,000 in 2.5% dry milk TBS/Tween and allowed to bind 40 minutes.  The membranes 
were washed and peroxidase-conjugated secondaries were allowed to bind 40 minutes 
(1:25,000 dilution).   After careful washing, the membranes were bathed in a 
chemiluminescent-specific substrate available from Pierce.  The membranes were 
exposed to film for 5 minutes, 10 minutes, and 30 minutes and then developed in the dark 
room. 
 The Far Westerns performed and developed with this more sensitive detection 
method did reveal some interactions (Figure B.9).  The thrombin Far Western (primary 
antibody to thrombin) indicates the TAT complex binds to the 151-250 polypeptide and 















a. Thrombin Far Western 












b. Antithrombin Far Western 
Figure B.9:  Far Western Results of the Interaction Between Vitronectin 
Polypeptides and TAT. 
These are 5 minute exposure films of Far Westerns of vitronectin polypeptides
incubated with the thrombin-antithrombin complex.  Approximately 10µg of each
polypeptide was loaded on 15% SDS-PAGE and transferred to Immobilon™.  Complex
was allowed to bind overnight and then the membrane was incubated with primary
antibodies to both thrombin (a.) and antithrombin (b.) diluted 1:25,000 in 2.5% dry milk
in TBS/Tween.  An interaction between the polypeptides and the thrombin-antithrombin
complex is detected by chemilluminescence between polypeptides 151-250 and 251-350
on both blots.  In addition, the antithrombin blot indicates an interaction at 201-300 and









polypeptides:  151-250, 201-300, 251-350, and 351-459.  The Far Westerns were 
repeated and revealed the same interactions.   
 Even though thrombin and antithrombin form a complex that should be identified 
by a primary antibody to either component of the pair, both an antibody to thrombin and 
an antibody to antithrombin were employed in the Far Westerns.  This was done to be 
more thorough in evaluation of TAT interaction and also to corroborate data generated by 
each antibody.  The thrombin Far Western gave a signal with only two polypeptides, 
while the antithrombin Far Western gave a signal with four polypeptides.  There are a  
number of possibilities to explain this result.  The primary antibodies are both polyclonals 
that are known to recognize their respective proteins and the TAT complex.  The two 
additional interactions indicated with the antithrombin antibody could have been a result 
of non-specific binding or genuine interactions of vitronectin with the TAT complex. 
Perhaps the interaction was not detected with the thrombin antibody due to antibody 
interference from association of TAT with the polypeptide.  
 Thrombin-antithrombin complex formation was achieved by mixing together a 
1:1.5 molar ratio of thrombin:antithrombin.  Although the thrombin component is 
responsible for the interaction of the TAT complex with vitronectin, excess free 
antithrombin could have interacted with the polypeptides and then given a false positive 
signal upon the addition of antithrombin antibody, although this possibility seems highly 
unlikely.   
 In any event, the 151-250 and 251-350 interactions are corroborated by both 
thrombin antibody and antithrombin antibody Far Westerns.  The 151-250 polypeptide 
lies within the first hemopexin homology domain.  The 251-351 spans both hemopexin 
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domains and does include part of the heparin binding region where TAT has been 
speculated to interact.   
 
IV.  Discussion 
 Vitronectin performs many physiological roles due to its interactions with 
multiple ligands.  Many of these interactions have been studied extensively to elucidate 
vitronectin function.  Binding determinants have been concurrently localized, giving 
credence to a domain organization of the protein.  Ligand-binding regions have been 
assigned with a relative degree of confidence from various groups/techniques reporting 
similar findings.  Heparin-binding to vitronectin is such an example, as well as a high-
affinity binding site in the SMB domain for PAI-1.  However, the binding region(s) for 
the thrombin-antithrombin complex have not been elucidated.  The ternary complex 
formation of TAT with vitronectin is a very important event that warrants closer 
examination.  The association of thrombin with antithrombin has been well characterized, 
but much is still unknown about what happens when the TAT complex encounters multi-
functional vitronectin.   
 Work with mABs and cleavage products of vitronectin by de Boer et al. suggests 
the region on vitronectin responsible for interaction with TAT is the N-terminal region 
(16).  Earlier studies by the same group demonstrated that the ternary complex bound 
endothelial cells via the heparin-binding region of vitronectin, thus this region could not 
be involved in the formation of the VN-TAT complex (92).  Another site had to be 
responsible.   
 61
 Although recombinant polypeptides have been used to localize ligand binding 
sites on vitronectin for some molecules, they have not been employed in assays with the 
thrombin-antithrombin complex.  Using bacterial recombinants, this project reports the 
possibility of two TAT binding regions on vitronectin, one spanning amino acids 151-
250, the other amino acids 251-350.  Interactions were detected by Far Western, a 
technique utilized by many groups to study protein-protein interactions.  Two other 
points of interaction are reported from the antithrombin antibody Far Western, but these 
interactions are not seen in the thrombin Far Western.  This does not throw out their 
validity as genuine points of interaction, but neither does it strengthen their case. 
 Far Westerns are derivations of Western blots, and certain limitations exist in 
these assays.  Results from experiments that capitalize on immobilized protein must be 
interpreted carefully.  Conformationally-dependent binding determinants are often 
undetectable in such assays due to fold disruption.  It is also assumed many times when 
conducting these experiments that epitopes are independent; multivalency effects are 
often lost.  Additionally, when electroblotting proteins, it is difficult to determine 
accurate amounts or concentrations of proteins that actually end up being assayed.    
Furthermore, preparations of the polypeptides and proteins are subject to 
consideration.  Recombinant expression in E. coli renders a polypeptide devoid of any 
post-translational modifications.  In some cases, phosphorylation of vitronectin has 
proven important for ligand binding.  Such knowledge must be noted in any ligand-
binding study that utilizes polypeptides devoid of such modifications, such as this one.  
Also, when using “pieces” of proteins, whether recombinantly expressed polypeptides, 
synthetic peptides, or proteolytic fragments, there is always the possibility that a binding 
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site has been disrupted by the separation technique (cleavage or engineering).  Assays 
with prepared peptides are also often highly susceptible to experimental artifact. 
Still, the data collected and reported here has value.  The interaction of two 
polypeptides suggests two possible binding sites.  The stoichiometry of the ternary 
complex of VN-T-AT appears to be 1:1:1, although vitronectin has demonstrated 
interesting binding stoichiometries with thrombin alone (197).  (The ternary complex 
migrates at approximately 160kDa in non-reducing condtions.)  Detection of two regions 
of interaction could suggest a different binding stoichiometry, but it is highly unlikely.    
Polypeptide 151-250 spans hemopexin homology domain I.  No reports of TAT 
binding have been mapped here or ever speculated.  The 251-350 polypeptide spans part 
of the heparin-binding region, which has been eliminated experimentally as a region for 
binding.  However, this polypeptide spans 90 amino acids that are not part of the heparin 
binding region, so another epitope could very possibly lie within that region.      
          
V.  Future Experiments 
 This work poses two possible regions for TAT interaction with vitronectin.  
Further experiments should include competitive binding experiments with monoclonals  
of known epitope, a method extensively used and reported in the literature.  The 
polypeptides should also be examined for binding to thrombin alone.  Working under the 
assumption that thrombin is the binding component of the TAT pair that interacts with 
vitronectin, it would be interesting to see if similar results are discovered.  Eventually, 
once a polypeptide binds consistently in both Far Westerns and competitive binding 
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experiments, work should be done to elucidate specific residues important for binding 
using site-directed mutagenesis or synthetic peptides.    
 A successful purification protocol has been written and tested for each of the 
recombinant polypeptides.  Pure polypeptides have even reserved and placed in long-term 
storage and can be used in any number of subsequent experiments.  These polypeptides 
have served and will continue to serve as very useful reagents in elucidating information 













Monoclonal Antibody Characterization and Mapping 
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I. Introduction 
 Monoclonal antibodies are invaluable tools of biochemistry.  They are used in a 
wide variety of assays to ascertain various kinds of information.  Monoclonal antibodies 
have proven very important in vitronectin research.  They have been used generally to 
detect the presence of protein and more specifically to propose and localize the ligand 
binding sites of PAI-1 (86,96,102), plasminogen (86), TAT (16,92), collagen (104,198), 
complement complex (104), and heparin (104) to vitronectin.  For localization of regions 
of ligand interaction, it is often advantageous and sometimes necessary to know the 
specific region of vitronectin to which a certain antibody maps, such as competition 
assays.  Thus, when a new monoclonal has been generated, it must be further 
characterized to be fully appreciated.   
 Our laboratory has recently acquired eight murine monoclonal antibodies, one 
from Green Mountain, one from Quidel and six from Molecular Innovations (MI).    
Cindy Brown, a graduate student in the lab, has performed preliminary experiments with 
these antibodies to generally characterize their binding to vitronectin.   ELISA results 
indicate binding titers for this type of solid-phase assay and help to eliminate weakly-
binding monoclonals.   HPLC analysis is being conducted to resolve vitronectin-antibody 
complexes that can ultimately be isolated and utilized in crystallography trials.   
Vitronectin has been titrated at different ratios to antibody and preliminary results for two 





II. Experimental Procedures 
  Murine monoclonal antibodies to vitronectin were obtained from Green 
Mountain, Quidel, and Molecular Innovations (1D1, 1E9, 2C3, 8H1, 2A10, 4A1).  
Secondary peroxidase-conjugated anti-mouse antibodies were purchased from Vector 
Laboratories.  As a first step, the antibodies were tested for interaction with vitronectin in 
Western blotting.  5 µg native vitronectin was loaded on 10% SDS-PAGE and transferred 
to nitrocellulose via a BioRad Semi-dry Blotter at 20V for 20 minutes.  The blots were 
blocked for 1 hour in 10% dry milk in PBS/0.1% Tween and then incubated with the 
monoclonals at ELISA-determined titers (as a starting dilution) for 1 hour. After washing, 
secondary peroxidase-conjugated anti-mouse antibodies were allowed to bind and 
detection was visualized upon addition of peroxide substrate.  
Epitope mapping of the antibodies was performed by loading 10 µg of each 
polypeptide on 15% SDS-PAGE and performing a Western blot as previously described; 
both chromagenic and chemiluminescent development were used.  Epitope mapping 
experiments were repeated.   
 
III. Results 
As a first step in characterizing these monoclonals, it was important to establish 
that they could be used in immunoblotting experiments, namely Westerns.  A chart 
summarizing the ELISA and Western data for the eight monoclonal antibodies is found in 
Table III.   Three of the eight monoclonals ( 4A1, 2A10, 8H1) were determined to bind 
poorly to solid phase vitronectin based on the ELISA experiments.  Western blots were 




Table III:  Summary of ELISA and Western Results for Monoclonals. 
   ELISA    Western 
Antibody   effective concentration            concentration tested         Signal§ 
   (µg/ml)*  (µg/ml) 
 
Green Mountain  0.052   0.052      + 
 
Quidel    0.6   0.6      + 
MI-1D1   0.3   0.3      + 
 
MI-1E9   0.32   0.32      +   
 
MI-2C3   0.86   0.86      + 
 
MI-4A1   ---   0.4      + 
 
MI-2A10  ---   0.2     ---  
 




Eight monoclonal antibodies were assays with native vitronectin in both ELISA experiments 
and Western blots.  *Cindy Brown performed the ELISA experiments, while Western blots 
were incubated with dilutions of the monoclonals based on the effective titers calculated from 
the ELISAs.  §A “+” denotes a positive interaction between native vitronectin and the 





ELISA titers or a 1:1000 dilution of the company provided stock. Native vitronectin was 
immunoblotted onto nitrocellulose and incubated with the monoclonals.  Six (Green 
Mountain, Quidel, MI-1D1, MI-1E9, MI-2C3, MI-4A1) of the eight monoclonals gave a 
positive signal on the Western blot (Figure C.1a).  These six were further characterized 
by Western blot with the vitronectin polypeptides. 
 Approximately 10 µg of each polypeptide was loaded, along with a native 
vitronectin control, on 15% SDS-PAGE.  The polypeptides were electroblotted first onto 
nitrocellulose and incubated with one of the monoclonals.   Polypeptide 51-150 gave a 
positive signal on the Quidel blot (Figure C.1b), and polypeptides 101-200 and 351-459 
gave a positive signal on the MI-2C3 blot (Figure C.1c).  2C3 is a monoclonal antibody, 
so the detection of two potential binding sites for 2C3 is suspicious and probably caused 
by non-specific binding, although anything is possible when testing “uncharacterized” 
tools.   
On the blots incubated with Green Mountain, MI-1D1, MI-1E9, and MI-4A1, no 
color development resulted except for the full length vitronectin control.  A concern arose 
that blocking conditions were too severe, so the Westerns were repeated and blocked only 
for 45 minutes in 5% milk/PBS, but similar blots resulted with no development.  As was 
the case for the Far Westerns, a more sensitive detection method was sought after, and 
again chemiluminescent development was employed for subsequent Westerns.  When 
this detection method was used, results for Green Mountain, 1D1, and 1E9 were the 
same.  No interaction with the polypeptides was detected.  This suggests that these 
monoclonals recognize epitopes that are conformationally-dependent and structural 
binding requirements are disrupted when the polypeptides are prepared or immobilized.  
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Figure C.1:  Antibody Mapping. 
In (a.), 5.0 µg of full length vitronectin was loaded on 10% SDS-PAGE 
and Western blotted to nitrocellulose.  The membrane was cut into seven
strips and incubated with seven different murine monoclonal antibodies to
vitronectin.  The first five pictured indicated interaction, while the last two
do not.  Quidel (b.), MI-2C3 (c.) and MI-4A1 (d.) antibodies were 
incubated with blotted polypeptides.  Quidel maps to polypeptide 51-150. 
2C3 maps to polypeptides 101-200 and 351-459.  4A1 maps to 
polypeptides 101-250 and 151-251.   (b.) and (c.) are pictures of 
nitrocellulose developed using chromagenic detection.  (d.) is a picture of
X-ray film exposed for one minute to Immobilon™ as part of a





















MI-4A1, however, gave a positive result in binding to polypeptides 101-200 and 
151-250 (Figure C.1d).  The binding of two consecutive polypeptides is very 
encouraging.  These polypeptides overlap, and such a pattern of binding could be 
interpreted as two binding sites or the same binding within the overlapping region.  For 
4A1, one binding site could potentially be between 151-200, which localizes the binding 
to 50 amino acids instead of 100.   Interestingly, on the full length vitronectin control for 
2C3, the antibody recognizes the low molecular weight band of the two chain form of 
vitronectin, which is usually not visualized by Coomassie staining.  This band is a 10kDa 
peptide that results from the cleavage at residue 379.  I would expect an antibody that 
recognizes the low molecular weight band to bind the 351-459 polypeptide, but that is not 
the case here.  
 
IV.  Discussion 
 There are several published techniques that have been used to map monoclonal 
antibodies to vitronectin, some very direct and some very elegantly designed.  The 
approach used here is a direct one and capitalizes on the recombinant polypeptides of 
vitronectin previously expressed and purified.  Eight monoclonal antibodies have been 
acquired by this laboratory.  Six were found to bind full-length vitronectin in Western 
immunoblotting experiments.  Green Mountain, MI-1D1, and MI-1E9 do no appear to 
have linear epitopes that can be mapped by the method employed here.  Three others—
Quidel, MI-2C3, and MI-4A1—seem to bind the polypeptides with high affinity and 
recognize linear epitope(s) that have been successfully localized.  Quidel maps to 101-
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200; 2C3 interacts with two non-consecutive polypeptides, 101-200 and 351-49; 4A1 
maps to 101-200 and 151-250, or is perhaps localized more specifically to 151-200.     
  
V.  Future Experiments 
 In order to acquire epitope information for Green Mountain, 1D1, and 1E9 
monoclonal antibodies, native gels should be run with polypeptides or cleavage products 
to gain insight on the recognition regions for these monoclonals that did not give a signal 
on SDS-PAGE Westerns.   
 Any of the monoclonals that map with some degree of confidence and consistency 
becomes a candidate for co-crystallization trials.  These will also be used to study 
interactions of vitronectin with its many ligands and generally to detect presence of 
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DQESCKGRCT EGFNVDKKCQ CDELCSTTQS CCTDYTAECK PQVTRGDVFT 
NPEDEYTVYD DGEEKNNATV HEQVGGPSLT SDLQAQSKGN PEQTPVLKPE  
 
Amino Acid Composition 
residue number mole percent 
A 3 2.439 
B 0 0.0 
C 8 6.504 
D 9 7.317 
E 12 9.756 
F 2 1.626 
G 10 8.130 
H 8 6.504 
I 0 0.0 
K 7 5.691 
L 6 4.878 
M 3 2.439 
N 4 3.252 
P 7 5.691 
Q 8 6.504 
R 3 2.439 
S 11 8.943 
T 9 7.317 
V 8 6.504 
W 0 0.0 
Y 5 4.065 
Z 0 0.0 
 


















NPEDEYTVYD DGEEKNNATV HEQVGGPSLT SDLQAQSKGN PEQTPVLKPE 
EEAPAPEVGA SKPEGIDSRP ETLHPGAPQP PAEEELCSGK PSTLHRLKNG 
 
Amino Acid Composition 
residue number mole percent 
A 7 5.645 
B 0 0.0 
C 1 0.806 
D 8 6.452 
E 16 12.903 
F 2 1.613 
G 11 8.871 
H 9 7.258 
I 1 0.806 
K 6 4.839 
L 8 6.452 
M 3 2.419 
N 4 3.226 
P 15 12.097 
Q 5 4.032 
R 3 2.419 
S 11 8.871 
T 6 4.839 
V 6 4.839 
W 0 0.0 
Y 2 1.613 
Z 0 0.0 
 




















EEAPAPEVGA SKPEGIDSRP ETLHPGAPQP PAEEELCSGK PSTLHRLKNG 
SLFAFRGQYC YELDEKAVRP GYPKLIRDVW GIEGPIDAAF TRINCQGKTY 
 
Amino Acid Composition 
residue number mole percent 
A 9 7.317 
B 0 0.0 
C 3 2.439 
D 6 4.878 
E 12 9.756 
F 5 4.065 
G 13 10.569 
H 8 6.504 
I 5 4.065 
K 6 4.878 
L 8 6.504 
M 2 1.626 
N 2 1.626 
P 13 10.569 
Q 3 2.439 
R 7 5.691 
S 9 7.317 
T 4 3.252 
V 4 3.252 
W 1 0.813 
Y 3 2.439 
Z 0 0.0 
 
 



















SLFAFRGQYC YELDEKAVRP GYPKLIRDVW GIEGPIDAAF TRINCQGKTY 
LFKGSQYWRF EDGVLDPDYP RNISDGFDGI PDNVDAALAL PAHSYSGRER 
 
Amino Acid Composition 
residue number mole percent 
A 8 6.452 
B 0 0.0 
C 2 1.613 
D 11 8.871 
E 6 4.839 
F 6 4.839 
G 14 11.290 
H 8 6.452 
I 6 4.839 
K 4 3.226 
L 9 7.258 
M 2 1.613 
N 4 3.226 
P 8 6.452 
Q 3 2.419 
R 8 6.452 
S 9 7.258 
T 2 1.613 
V 5 4.032 
W 2 1.613 
Y 7 5.645 
Z 0 0.0 
 




















LFKGSQYWRF EDGVLDPDYP RNISDGFDGI PDNVDAALAL PAHSYSGRER 
VYFFKGKQYW EYQFQHQPSQ EECEGSSLSA VFEHFAMMQR DSWEDIFELL 
 
Amino Acid Composition 
residue number mole percent 
A 6 4.839 
B 0 0.0 
C 1 0.806 
D 10 8.065 
E 10 8.065 
F 9 7.258 
G 10 8.065 
H 10 8.065 
I 3 2.419 
K 3 2.419 
L 8 6.452 
M 4 3.226 
N 3 2.419 
P 6 4.839 
Q 7 5.645 
R 6 4.839 
S 13 10.484 
T 0 0.0 
V 5 4.032 
W 3 2.419 
Y 7 5.645 
Z 0 0.0 
 




















VYFFKGKQYW EYQFQHQPSQ EECEGSSLSA VFEHFAMMQR DSWEDIFELL 
FWGRTSAGTR QPQFISRDWH GVPGQVDAAM AGRIYISGMA PRPSLAKKQR 
 
Amino Acid Composition 
residue number mole percent 
A 7 5.654 
B 0 0.0 
C 1 0.806 
D 5 4.032 
E 8 6.452 
F 8 6.452 
G 11 8.871 
H 10 8.065 
I 4 3.226 
K 4 3.226 
L 6 4.839 
M 6 4.839 
N 0 0.0 
P 6 4.839 
Q 10 8.065 
R 8 6.452 
S 14 11.290 
T 3 2.419 
V 5 4.032 
W 4 3.226 
Y 4 3.226 
Z 0 0.0 
 




















FWGRTSAGTR QPQFISRDWH GVPGQVDAAM AGRIYISGMA PRPSLAKKQR 
FRHRNRLGYR SQRGHSRGRN QNSRRPSRAT WLSLFSSEES NLGANNYDDY 
 
Amino Acid Composition 
residue number mole percent 
A 7 5.645 
B 0 0.0 
C 0 0.0 
D 5 4.032 
E 3 2.419 
F 4 3.226 
G 13 10.484 
H 10 8.065 
I 3 2.419 
K 3 2.419 
L 7 5.645 
M 5 4.032 
N 6 4.839 
P 6 4.839 
Q 6 4.839 
R 17 13.710 
S 17 13.710 
T 3 2.419 
V 3 2.419 
W 3 2.419 
Y 3 2.419 
Z 0 0.0 
 




















FRHRNRLGYR SQRGHSRGRN QNSRRPSRAT WLSLFSSEES NLGANNYDDY 
RMDWLVPATC EPIQSVFFFS GELYYRVNLR TRRVDTVDPP YPRSIAQYW  
LGCPAPGHL 
 
Amino Acid Composition 
residue number mole percent 
A 5 3.759 
B 0 0.0 
C 2 1.504 
D 7 5.263 
E 4 3.008 
F 5 3.759 
G 10 7.519 
H 10 7.519 
I 2 1.504 
K 2 1.504 
L 9 6.767 
M 4 3.008 
N 7 5.263 
P 9 6.767 
Q 4 3.008 
R 18 13.534 
S 16 12.030 
T 3 2.256 
V 6 4.511 
W 3 2.256 
Y 7 5.263 
Z 0 0.0 
 
 















APPENDIX B:  Polypeptide Modeling 
Using INSIGHT© software, the following polypeptides were highlighted in the predicted 

























































































This is the mature vitronectin peptide sequence organized into four domains.  
Green indicates the N-terminal domain, gray is the connecting region, orange 
represents hemopexin homology domain (HPD) I, and blue is hemopexin 
homology domain II.  An ▼ indicates an exon junction.  HPD I and II are 
further organized into four and three parts, respectively, to indicate individual 
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